Richard joined Ensem Therapeutics in September 2024 as Vice President of Finance & Accounting, bringing over 20 years of finance and accounting experience across the life science and software industries. Previously, Richard served as the Vice President of Finance & Accounting at Frequency Therapeutics, a biotechnology company focused on regenerative medicine. At Frequency, he was their first finance department hire and successfully scaled their accounting and finance function. He also established their SEC reporting and SOX compliance functions and prepared the company for their successful IPO.
Prior to Frequency, Richard was the Corporate Controller with Semprus Biosciences, a biomedical device company, where he managed the due diligence for their acquisition and integration with Teleflex and oversaw their end-to-end accounting and finance functions. Throughout his earlier career, Richard worked with various early-stage biotechnology & software organizations. Richard is well versed in strategic planning, change management, technical implementations, and process improvement initiatives.

Richard holds a Bachelor of Science in Accounting from Bentley University.